Lower cholesterol and iron levels, alongside higher glucose, uric acid, and liver enzymes, are associated with a reduced chance of living to 100. These findings suggest a link between specific blood biomarkers and exceptional longevity, offering potential insights into the biological factors behind longer life expectancy.
September 2023 – Gero Science
Key Takeaways
- Lower cholesterol and iron levels: Research suggests that individuals with lower cholesterol and iron levels are more likely to live longer. Excess cholesterol can lead to cardiovascular issues, while high iron levels may cause oxidative stress and damage. Managing these biomarkers through diet or medical intervention may help reduce age-related health risks and promote longevity.
- Higher glucose, uric acid, and liver enzymes: Elevated glucose, uric acid, and liver enzyme levels are linked to a reduced likelihood of reaching 100. High glucose levels increase the risk of diabetes and metabolic disorders, while elevated uric acid is associated with conditions like gout. Abnormal liver enzymes often signal poor liver function. Addressing these factors through lifestyle changes may improve long-term health outcomes.
- Biomarker profiles as longevity predictors: Blood biomarkers provide a window into one’s biological ageing process. Patterns of specific markers can help predict a person’s health trajectory and potential lifespan. Understanding these patterns allows for tailored health interventions, improving an individual’s chances of reaching advanced ages in good health.
Continuously monitoring biomarkers such as cholesterol, glucose, and liver function offers crucial insights into a person’s overall health. Long-term tracking helps detect early signs of ageing-related decline, allowing for preventative measures that can slow ageing processes and maintain healthspan, the years lived in good health.
Read the article at: Vivekanantham, Sayinthen, et al. “Blood Biomarker Profiles and Exceptional Longevity: Comparison of Centenarians and Non-Centenarians in a 35-Year Follow-Up of the Swedish AMORIS Cohort.” GeroScience, Springer, 2023,